Martin Stanley Hirsch, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometriosis | 4 | 2022 | 870 | 1.390 |
Why?
|
| Anti-HIV Agents | 25 | 2015 | 4527 | 1.310 |
Why?
|
| HIV-1 | 23 | 2013 | 6863 | 1.030 |
Why?
|
| Clostridium botulinum | 2 | 2014 | 21 | 0.920 |
Why?
|
| Botulism | 2 | 2014 | 21 | 0.910 |
Why?
|
| Drug Resistance, Viral | 13 | 2012 | 862 | 0.890 |
Why?
|
| Reverse Transcriptase Inhibitors | 9 | 2008 | 621 | 0.840 |
Why?
|
| Nandrolone | 1 | 2022 | 17 | 0.820 |
Why?
|
| Botulinum Toxins | 2 | 2014 | 189 | 0.790 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2012 | 113 | 0.760 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2012 | 254 | 0.670 |
Why?
|
| HIV Infections | 29 | 2013 | 17351 | 0.620 |
Why?
|
| Mentors | 1 | 2023 | 661 | 0.600 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 116 | 0.600 |
Why?
|
| Piracetam | 1 | 2018 | 88 | 0.600 |
Why?
|
| Cough | 1 | 2021 | 594 | 0.580 |
Why?
|
| Anti-Retroviral Agents | 8 | 2013 | 1784 | 0.520 |
Why?
|
| Search Engine | 1 | 2016 | 143 | 0.500 |
Why?
|
| Fatigue | 2 | 2021 | 1552 | 0.500 |
Why?
|
| Communicable Diseases | 3 | 2011 | 875 | 0.490 |
Why?
|
| CA-125 Antigen | 1 | 2016 | 281 | 0.460 |
Why?
|
| CD4 Lymphocyte Count | 12 | 2013 | 2571 | 0.460 |
Why?
|
| Consumer Health Information | 1 | 2016 | 215 | 0.460 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2015 | 1897 | 0.440 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2008 | 1937 | 0.430 |
Why?
|
| Poultry Diseases | 1 | 2012 | 26 | 0.420 |
Why?
|
| Air Microbiology | 1 | 2013 | 95 | 0.400 |
Why?
|
| Orthomyxoviridae | 1 | 2013 | 149 | 0.390 |
Why?
|
| Influenza, Human | 2 | 2013 | 1521 | 0.380 |
Why?
|
| Encephalitis Virus, Eastern Equine | 2 | 2008 | 12 | 0.370 |
Why?
|
| Zoonoses | 1 | 2012 | 179 | 0.370 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 432 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 960 | 0.330 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2008 | 14 | 0.310 |
Why?
|
| Anticonvulsants | 1 | 2018 | 1906 | 0.310 |
Why?
|
| Pandemics | 3 | 2020 | 8654 | 0.310 |
Why?
|
| Drug Therapy, Combination | 12 | 2018 | 6310 | 0.290 |
Why?
|
| HIV Protease Inhibitors | 4 | 2003 | 432 | 0.290 |
Why?
|
| Human Development | 1 | 2007 | 123 | 0.270 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 1463 | 0.270 |
Why?
|
| Disease Transmission, Infectious | 1 | 2012 | 559 | 0.270 |
Why?
|
| Guanine | 1 | 2007 | 279 | 0.260 |
Why?
|
| Viral Proteins | 1 | 2012 | 1804 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7390 | 0.240 |
Why?
|
| Internet | 1 | 2016 | 3092 | 0.230 |
Why?
|
| Purine Nucleosides | 1 | 2003 | 30 | 0.230 |
Why?
|
| Dioxolanes | 1 | 2003 | 23 | 0.230 |
Why?
|
| Drug Monitoring | 4 | 2010 | 962 | 0.220 |
Why?
|
| Publishing | 1 | 2011 | 833 | 0.220 |
Why?
|
| Zidovudine | 3 | 2003 | 624 | 0.220 |
Why?
|
| Drug Interactions | 3 | 2019 | 1416 | 0.210 |
Why?
|
| Biomedical Research | 3 | 2015 | 3429 | 0.210 |
Why?
|
| West Nile Fever | 1 | 2003 | 74 | 0.210 |
Why?
|
| West Nile virus | 1 | 2003 | 76 | 0.210 |
Why?
|
| Hepatitis B, Chronic | 1 | 2007 | 410 | 0.210 |
Why?
|
| Epilepsy | 1 | 2018 | 3290 | 0.210 |
Why?
|
| Meningoencephalitis | 1 | 2003 | 83 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.200 |
Why?
|
| Cyclic N-Oxides | 1 | 2002 | 72 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.200 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2003 | 303 | 0.190 |
Why?
|
| Oxazines | 5 | 2006 | 350 | 0.190 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2022 | 116 | 0.190 |
Why?
|
| Humans | 57 | 2024 | 761504 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 4369 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7856 | 0.170 |
Why?
|
| Phloroglucinol | 1 | 2019 | 6 | 0.170 |
Why?
|
| Antibodies, Viral | 2 | 2008 | 3156 | 0.160 |
Why?
|
| Terpenes | 1 | 2019 | 96 | 0.160 |
Why?
|
| Imidazoles | 1 | 2005 | 1180 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 231 | 0.160 |
Why?
|
| Nelfinavir | 4 | 2005 | 68 | 0.160 |
Why?
|
| Lymphadenitis | 1 | 2019 | 99 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2019 | 412 | 0.150 |
Why?
|
| Developing Countries | 2 | 2007 | 2885 | 0.150 |
Why?
|
| Cross Infection | 1 | 2007 | 1422 | 0.150 |
Why?
|
| Macrophages | 1 | 2012 | 5769 | 0.140 |
Why?
|
| Alanine | 1 | 2020 | 609 | 0.140 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 270 | 0.140 |
Why?
|
| Antiviral Agents | 2 | 2007 | 3060 | 0.140 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 1749 | 0.140 |
Why?
|
| Drug Tolerance | 1 | 2018 | 367 | 0.140 |
Why?
|
| Drug Synergism | 3 | 2005 | 1755 | 0.130 |
Why?
|
| HIV | 2 | 2006 | 1582 | 0.130 |
Why?
|
| Female | 28 | 2022 | 392644 | 0.130 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2016 | 42 | 0.130 |
Why?
|
| RNA Virus Infections | 1 | 2015 | 19 | 0.130 |
Why?
|
| Poverty | 1 | 2007 | 2698 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2019 | 498 | 0.120 |
Why?
|
| Double-Blind Method | 7 | 2022 | 12341 | 0.120 |
Why?
|
| Pelvic Pain | 1 | 2016 | 298 | 0.120 |
Why?
|
| Treatment Failure | 7 | 2010 | 2645 | 0.110 |
Why?
|
| Confusion | 2 | 2008 | 278 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2008 | 662 | 0.110 |
Why?
|
| Authorship | 1 | 2016 | 284 | 0.110 |
Why?
|
| Piperidines | 1 | 2002 | 1656 | 0.110 |
Why?
|
| Health Personnel | 1 | 2007 | 3335 | 0.110 |
Why?
|
| Piperazines | 3 | 2010 | 2523 | 0.110 |
Why?
|
| Bioterrorism | 1 | 2013 | 144 | 0.100 |
Why?
|
| Fever | 3 | 2019 | 1618 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 2691 | 0.100 |
Why?
|
| Adult | 25 | 2021 | 221177 | 0.100 |
Why?
|
| Pyrimidines | 3 | 2010 | 3028 | 0.090 |
Why?
|
| Comprehension | 1 | 2016 | 621 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2003 | 5112 | 0.090 |
Why?
|
| Infertility, Female | 1 | 2016 | 760 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 212 | 0.090 |
Why?
|
| Pyridines | 1 | 2002 | 2875 | 0.090 |
Why?
|
| Lamivudine | 4 | 2003 | 366 | 0.090 |
Why?
|
| Viral Load | 9 | 2010 | 3332 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 10766 | 0.080 |
Why?
|
| Integrase Inhibitors | 1 | 2008 | 12 | 0.080 |
Why?
|
| RNA, Viral | 6 | 2010 | 2846 | 0.080 |
Why?
|
| Tropism | 1 | 2008 | 44 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2022 | 8631 | 0.080 |
Why?
|
| Disease Vectors | 1 | 2008 | 61 | 0.080 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2008 | 59 | 0.080 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2008 | 82 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2008 | 53 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1640 | 0.070 |
Why?
|
| Libya | 1 | 2007 | 9 | 0.070 |
Why?
|
| Reverse Transcription | 1 | 2007 | 47 | 0.070 |
Why?
|
| Virus Replication | 2 | 2007 | 2435 | 0.070 |
Why?
|
| Foreign Professional Personnel | 1 | 2007 | 9 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3466 | 0.070 |
Why?
|
| Alkynes | 5 | 2006 | 320 | 0.070 |
Why?
|
| Male | 20 | 2021 | 360804 | 0.070 |
Why?
|
| Capital Punishment | 1 | 2007 | 30 | 0.070 |
Why?
|
| Jurisprudence | 1 | 2007 | 109 | 0.070 |
Why?
|
| Cyclopropanes | 5 | 2006 | 432 | 0.070 |
Why?
|
| Benzoxazines | 5 | 2006 | 316 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2005 | 48 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 469 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 754 | 0.060 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2004 | 56 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12974 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1051 | 0.060 |
Why?
|
| Cytomegalovirus | 2 | 2006 | 756 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1664 | 0.060 |
Why?
|
| Encephalitis Virus, St. Louis | 1 | 2003 | 1 | 0.060 |
Why?
|
| Indinavir | 1 | 2003 | 73 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2012 | 2690 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2007 | 528 | 0.060 |
Why?
|
| Genes, pol | 1 | 2003 | 52 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2008 | 1527 | 0.050 |
Why?
|
| Encephalitis, Viral | 1 | 2003 | 58 | 0.050 |
Why?
|
| Anniversaries and Special Events | 1 | 2004 | 95 | 0.050 |
Why?
|
| Disease Reservoirs | 1 | 2003 | 121 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 151 | 0.050 |
Why?
|
| Middle Aged | 8 | 2021 | 220895 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2008 | 718 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 1844 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 465 | 0.050 |
Why?
|
| Drug Approval | 1 | 2008 | 814 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 640 | 0.050 |
Why?
|
| Animals | 5 | 2015 | 168459 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2016 | 3482 | 0.050 |
Why?
|
| Oximes | 1 | 2002 | 303 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2008 | 1390 | 0.040 |
Why?
|
| Hepatitis C | 2 | 2007 | 1584 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2007 | 1336 | 0.040 |
Why?
|
| Research Design | 1 | 2015 | 6180 | 0.040 |
Why?
|
| Dextromethorphan | 1 | 2019 | 37 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 831 | 0.040 |
Why?
|
| Treatment Outcome | 7 | 2018 | 64680 | 0.040 |
Why?
|
| Hypericum | 1 | 2019 | 58 | 0.040 |
Why?
|
| Aged | 3 | 2021 | 169289 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2019 | 1638 | 0.040 |
Why?
|
| Groin | 1 | 2019 | 106 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 8002 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 2199 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2003 | 1328 | 0.040 |
Why?
|
| Pregnancy | 4 | 2008 | 29874 | 0.040 |
Why?
|
| Nurses | 1 | 2007 | 2478 | 0.040 |
Why?
|
| Travel | 1 | 2003 | 796 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2016 | 54425 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39106 | 0.030 |
Why?
|
| Diarrhea | 1 | 2003 | 1318 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 4853 | 0.030 |
Why?
|
| Child | 2 | 2018 | 80153 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2019 | 803 | 0.030 |
Why?
|
| Headache | 1 | 2003 | 1256 | 0.030 |
Why?
|
| Edema | 1 | 2019 | 766 | 0.030 |
Why?
|
| United States | 3 | 2012 | 72334 | 0.030 |
Why?
|
| Viremia | 2 | 2009 | 707 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 9031 | 0.030 |
Why?
|
| Decision Making | 1 | 2008 | 3929 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 553 | 0.030 |
Why?
|
| Mutation | 4 | 2008 | 30052 | 0.030 |
Why?
|
| Stavudine | 2 | 2003 | 85 | 0.030 |
Why?
|
| Didanosine | 2 | 2003 | 151 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 888 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 1084 | 0.030 |
Why?
|
| Autoantigens | 1 | 2016 | 891 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 59243 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2004 | 3905 | 0.020 |
Why?
|
| Patient Selection | 1 | 2003 | 4244 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 88319 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 1320 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 80636 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2005 | 18965 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2707 | 0.020 |
Why?
|
| Physicians | 1 | 2007 | 4591 | 0.020 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2008 | 34 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2008 | 98 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 9177 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4111 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 2020 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2008 | 220 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2825 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1667 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 36426 | 0.020 |
Why?
|
| Health Services Administration | 1 | 2006 | 63 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2008 | 2151 | 0.020 |
Why?
|
| Ritonavir | 1 | 2007 | 329 | 0.020 |
Why?
|
| Foscarnet | 1 | 2004 | 35 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2004 | 252 | 0.010 |
Why?
|
| Genome, Human | 1 | 2016 | 4425 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6485 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13506 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 675 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.010 |
Why?
|
| Brain | 1 | 2008 | 27112 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2006 | 705 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1702 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2006 | 1359 | 0.010 |
Why?
|
| Acute Disease | 1 | 2009 | 7237 | 0.010 |
Why?
|
| Time Factors | 3 | 2005 | 39967 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2003 | 1071 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 3162 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 1036 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 3442 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3688 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 5869 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 5486 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4243 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 10508 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2006 | 2017 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4580 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 12990 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 14605 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2008 | 23995 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 17904 | 0.000 |
Why?
|